Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TJO-083
- Development stage
- Phase 2
- Lead developer
- Taejoon Pharmaceutical
- Administration
- Ophthalmic
01
Overview
TJO-083 is an investigational drug being studied for the treatment of dry eye disease. It is currently undergoing clinical trials to evaluate its efficacy and safety compared to standard treatments and placebo in patients with dry eye syndrome. The drug is administered over a 12-week period, with outcomes measured by improvements in corneal staining and relief of dry eye symptoms. The developer of TJO-083 is Taejoon Pharmaceutical. Its precise mechanism of action has not been disclosed in publicly available sources, but it is being positioned as a novel therapy for ocular surface disorders such as dry eye disease[1][2][3][4].
Beyond the preview
Go deeper on TJO-083.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TJO-083.